Bibliografisk note

Funding Information:
The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) was funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (P50HL112349; Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01912534).